REFERENCES
1.Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C,
Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens
RJ, Sadelain M. Long-Term Follow-up of CD19 CAR Therapy in Acute
Lymphoblastic Leukemia. N Engl J Med. 2018;378:449-59.
2. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C,
Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM,
Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne
AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for
acute lymphoblastic leukaemia in children and young adults: a phase 1
dose-escalation trial. Lancet. 2015;385:517-28.
3. Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC,
Brozek J, Glanville AR; ISHLT/ATS/ERS BOS Task Force Committee;
ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS
clinical practice guideline: diagnosis and management of bronchiolitis
obliterans syndrome. Eur Respir J. 2014;44(6):1479-1503.
4. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW,
Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte
RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D,
Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS,
Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of
Health Consensus Development Project on Criteria for Clinical Trials in
Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging
Working Group report. Biol Blood Marrow Transplant.
2015;21(3):389-401.e1.
5. Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J,
Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ,
Martin PJ, Storer BE, Inamoto Y, Chai X, Flowers MED, Lee SJ.
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset
Bronchiolitis Obliterans Syndrome after Hematopoietic Cell
Transplantation. Biol Blood Marrow Transplant. 2016;22(4):710-716.
6. Hamilton BK. Current approaches to prevent and treat GVHD after
allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ
Program. 2018;2018(1):228-235.
7. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S,
Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B,
Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS,
Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D,
Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA,
Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I
trials using Sleeping Beauty to generate CD19-specific CAR T cells. J
Clin Invest. 2016;126(9):3363-3376.
8. Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y, Han W, Xu L, Zhang X,
Liu K, Chang L, Xiao L, Huang X. Donor-derived CD19-targeted T cell
infusion induces minimal residual disease-negative remission in relapsed
B-cell acute lymphoblastic leukaemia with no response to donor
lymphocyte infusions after haploidentical haematopoietic stem cell
transplantation. Br J Haematol.2017;179(4):598–605.
9. Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei
Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei
Xiao,Xiaojun Huang. Donor-Derived CD19-Targeted T Cell Infusion
Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease
with No Response to Donor Lymphocytes after Allogeneic Hematopoietic
Stem Cell Transplantation. Engineering(BeiJing).2019; 5(1):150-155.
10. Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang
GB, Walker I, Carpenter PA, Griffith LM, Akpek G, Mohty M, Wolff D,
Pavletic SZ, Cutler CS. National Institutes of Health Consensus
Development Project on Criteria for Clinical Trials in Chronic
Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working
Group Report. Biol Blood Marrow Transplant.2015;21(8):1343–1359.
11.Vieira AG, Funke VA, Nunes EC, Frare R, Pasquini R. Bronchiolitis
obliterans in patients undergoing allogeneic hematopoietic SCT. Bone
Marrow Transplant. 2014;49(6):812–817.
12. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf
O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G,
Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK,
Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected
virus-specific T cells for B-cell malignancies relapsed after allogeneic
stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965-73.
13. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH,
Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto
AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuver
B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN. Allogeneic T Cells
That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of
B-Cell Malignancies That Progress After Allogeneic Hematopoietic
Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J
Clin Oncol. 2016;34(10):1112-21.